Saturday, 6 December 2014

» European early access programme for Carmeseal-MD(TM) Action Duchenne

» European early access programme for Carmeseal-MD(TM) Action Duchenne: "Phrixus Pharmaceuticals aims to demonstrate that Carmeseal-MD has beneficial effects in patients with Duchenne and Becker muscular dystrophy by delivering an improvement in cardiac and respiratory function via protection of heart muscle and diaphragm.   The drug acts as a molecular band-aid by binding to, and then sealing, microscopic tears in muscle cells caused by the lack of functional dystrophin.  This prevents the uncontrolled leakage of calcium which in turn increases the performance of heart muscle and diaphragm and prevents their degeneration."



'via Blog this'

No comments:

Post a comment